BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 23, 2026
Home » Blogs » BioWorld MedTech Perspectives » Tax talk: 2017 or bust

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Tax talk: 2017 or bust

Oct. 23, 2015
By Mark McCarty

In a hurry? He's not.
Not holding his breath

FDA's device center is busily punching up draft guidances again, but today we're back into the faces-and-places discussion just like last time here at MDD Perspectives. This time, the churn is on Capitol Hill, which is also where two tax issues seem likely to end up on a more or less fast track to nowhere.

Paul Ryan's dirty job

Let's get one thing out of the way quickly. If you were Paul Ryan, would you want the job of Speaker of the House of Representatives? I'd pass, but it appears he has corralled a lot of the wayward tempers in the GOP. Still, there's time for him to think better of this idea.

Corporate American might think the problem with Ryan as speaker is that the tax reform push may lose steam over the near term. Nothing against Kevin Brady, but Ryan has a brand Brady lacks, so one has to wonder if tax reform is going to suffer if Ryan does indeed take the job, which by some accounts is a near certainty.

Of course, speaker Ryan would have the clout to make tax reform a priority, but how quickly will things move in the Ways and Means Committee if he's not there? There's little time left to act this year, and next year is an election year. All things considered, corporate tax reform may have to wait until 2017, and we'll see if the new occupant of the Oval Office is more interested in doing something both parties can accept than the incumbent.

Hitchhiker beware

The device tax repeal is back in vogue again, thanks to efforts on the part of House and Senate Republicans to repeal the Affordable Care Act. The House of Representatives passed a bill that would repeal much but not all of the ACA – including the device tax – and the authors of the bill apparently intended this legislation to show up in the Senate as a budget reconciliation bill, thus requiring only 51 votes for passage.

The problem? The Senate parliamentarian said the first edition of the House bill doesn't qualify as a budget reconciliation document. Ergo, any Senate vote on that bill would need 60 votes, which means the GOP would have had to bring over six votes from among 44 Democrats and two independents who caucus with them. As the saying goes, good luck with that.

Rep. Tom Price of Georgia has offered an amendment to the House bill that would pull the repeal of the Independent Payment Advisory Board to get the House bill in under the budget reconciliation requirement, but there are those who continue to insist on an all-or-nothing approach.

It's tough to predict how this Obamacare repeal push will work out on Capitol Hill, but it's really all for naught, isn't it? There is no way President Obama will sign anything like this, but getting a bill to the President's desk would at least look good on the campaign trail next year.

GOP leaders tried to tie the device tax repeal to the debt ceiling discussion in 2013, but the Senate leadership seems ill-disposed to try that again this year. Hence, it's safe to conclude that the device tax repeal is another 2017-or-bust item.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 23, 2026.
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • Illustration of magnifying glass inspecting brain

    Neurotrimin unveiled as marker in intellectual disability

    BioWorld Science
    Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing